Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-03-14 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed document of the Company in relation to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance. It is addressed to stock exchanges and signed by the company secretary. The document length is short (1414 characters) and it primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial data or detailed report content. This fits the description of a Regulatory Filing (RNS), which includes officer certifications and compliance confirmations.
2025-03-14 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2025-03-07 English
Updates
Regulatory Filings
2025-03-07 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission from a regulatory authority (Central Drugs Standard Control Organisation) to import a new pharmaceutical formulation for sale or distribution. The content is an intimation or announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1585 characters) and it serves as a notification to the stock exchanges rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-06 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission from a regulatory authority (Central Drugs Standard Control Organisation) for importing a new pharmaceutical formulation. The content is an intimation or announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1585 characters) and it serves as a notification to the stock exchanges rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-06 English
Please find the enclosed intimation of the Company as per the captioned subject.
Interim / Quarterly Report Classification · 98% confidence The document is a detailed announcement from AstraZeneca Pharma India Limited dated February 11, 2025, reporting unaudited financial results for the quarter and nine months ended December 31, 2024. It includes comprehensive financial tables with income, expenses, profit, tax, and earnings per share data. The document also contains an Independent Auditors' Review Report, which confirms the review of the unaudited financial results in accordance with Indian Accounting Standards, specifically Ind AS 34 for Interim Financial Reporting. Additionally, there is a press release summarizing the financial performance and commentary from company executives. The presence of unaudited financial statements for a quarter and nine months, along with an auditor's limited review report, aligns with the characteristics of an Interim / Quarterly Report. The document is substantive and exceeds 5,000 characters, containing actual financial data and analysis, not merely an announcement or certification. Therefore, it should be classified as an Interim / Quarterly Report (IR).
2025-03-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.